Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
PHILADELPHIA, May 28, 2021 /PRNewswire/ -- Ibere Pharmaceuticals (NYSE:IBER) (the "Company") today announced that it received a notice on May 25, 2021 from the New York Stock Exchange (the "NYSE") indicating that the Company is not in compliance with Section 802.01E of the NYSE Listed Company Manual as a result of its failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2021 (the "Quarterly Report") with the Securities and Exchange Commission (the "SEC"). The notice has no immediate effect on the listing of the Company's stock on the NYSE. As disclosed in the Company's Form 12b-25 filed with the SEC on May 18, 2021, on April 12, 2021 the Staff of the SEC re
15-12G - IBERE PHARMACEUTICALS (0001835205) (Filer)
25-NSE - IBERE PHARMACEUTICALS (0001835205) (Subject)
8-K - IBERE PHARMACEUTICALS (0001835205) (Filer)
SC 13G - IBERE PHARMACEUTICALS (0001835205) (Subject)
SC 13G/A - IBERE PHARMACEUTICALS (0001835205) (Subject)
SC 13G - IBERE PHARMACEUTICALS (0001835205) (Subject)